Evidence map›Paper›PMID 36842093›Full record

ArticlePain and therapy2023

Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study.

Reto Agosti, Catherine Parzini, Oliver Findling, Peter Myers, Jens A Petersen, Philippe Ryvlin, Peter Sandor, Matthias Stallmach, Chiara Zecca, Josefin Snellman and 4 more

Open access · goldAbstract read
In one paragraph

Article in Pain and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Reto AgostiKopfwehzentrum Hirslanden Zürich, Forchstrasse 424, 8702, Zollikon, Switzerland.
Catherine ParziniCabinet Dr. med. Catherine Parzini, 10 Place du Marché-1227, Carouge, Geneva, Switzerland.
Oliver FindlingKantonsspital Aarau AG, Tellstrasse 25, 5001, Aarau, Switzerland.
Peter MyersCabinet Dr. med. Peter John Myers, Neurologue FMH7, Ruelle du Couchant, 1207, Geneva, Switzerland.
Jens A PetersenUniversity Hospital Zurich and Neurozentrum, Schänzlistrasse 45, 3013, Bern, Switzerland.
Philippe RyvlinCHUV Departement des Neurosciences Cliniques, Rue du Bugnon 21, 1011, Lausanne, Switzerland.
Peter SandorRehaClinic AG, Quellenstrasse 34, 5330, Bad Zurzach, Switzerland.
Matthias StallmachNeurologie Am Schaulager, Emil-Frey-Str. 85, 4142, Münchenstein, Switzerland.
Chiara ZeccaNeurocenter of Southern Switzerland, EOC, Ospedale Regionale di Lugano, Via Tesserete 46, 6900, Lugano, Switzerland.
Josefin SnellmanNovartis Pharma AG, Lichtstrasse 35, 4056, Basel, Switzerland.
Shannon RitterNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA.
Michael E ArztNovartis Pharma Schweiz AG, Suurstoffi 14, 6343, Rotkreuz, Switzerland.
Simon RohrerNovartis Pharma Schweiz AG, Suurstoffi 14, 6343, Rotkreuz, Switzerland.
Andreas R GantenbeinZURZACH Care AG, Quellenstrasse, 34 5330, Bad Zurzach, Switzerland. andreas.gantenbein@zurzachcare.ch.
Novartis (Switzerland) · CHGastroZentrum Hirslanden Zürich · CHKantonsspital Aarau · CHNovartis (United States) · USSophia Genetics (Switzerland) · CHStiftung für Forschung in Spätantike und Mittelalter HR. Sennhauser · CHUniversità della Svizzera italiana · CHUniversity Hospital of Lausanne · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is limited real-world evidence on the burden of migraine among patients with prior preventive treatment failure (PPTF). In the BECOME Swiss subanalysis, we aimed to assess current prevalence of PPTF in patients with migraine seen at specialised headache centres in Switzerland and burden of migraine in these patients. Furthermore, we assessed this burden in subgroups stratified by monthly migraine days (MMDs) and number of PPTFs.

methodsBECOME was a prospective, multicentre, non-interventional two-part study conducted in 17 countries across Europe and Israel. This subanalysis includes patients visiting ten headache specialist centres in Switzerland. In part 1, patients visiting the centres over 3 months were screened by physicians for frequency of PPTF, MMD and other migraine characteristics. Patients with ≥ 1 PPTF and ≥ 4 MMDs were invited to take part in part 2. The primary endpoint was the proportion of patients with ≥ 1 PPTF (part 1). Other endpoints included proportion of patients specified by number of PPTF and MMD (part 1, part 2), and impact of migraine on patient-reported outcomes (PROs; part 2).

resultsPatients (1677) from ten Swiss centres were included in part 1, of which 855 (51.0%) reported ≥ 1 PPTF. One hundred fifty-five patients were included in part 2: 6.5% reported ≥ 4 PPTFs and 43.2% reported ≥ 15 MMDs. Mean EuroQoL 5 and EuroQoL visual analogue scale (EQ-VAS) were 0.8 ± 0.2 and 69.6 ± 20.2, respectively, suggesting a mild level of impairment in the daily functioning and self-reported health of the patients. Mean six-item Headache Impact Test (HIT-6) and modified Migraine Disability Assessment (mMIDAS) scores were 63.3 ± 6.5 and 22.7 ± 21.8, respectively, corresponding to severe migraine burden. Patients also reported impairment in work-related productivity and general activities (48.6 ± 22.8) but no associations of anxiety (7.2 ± 4.4) or depression (6.0 ± 4.4) with migraine were noted. Burden of migraine increased with increasing frequency of PPTF and MMD.

conclusionsMigraine-related quality of life, as well as work productivity are significantly affected in Swiss patients with migraine. Increasing migraine burden is associated with increasing migraine frequency and prior treatment failures.

Indexed as

Cross-sectional studyHeadacheMigraine disordersQuality of lifeReal-world evidenceSurveys and questionnairesSwitzerlandTreatment failure

Identifiers

PMID36842093
PMCPMC10036704
OpenAlexW4322100977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.